NeoGenomics, Inc.: NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
FT. MYERS, FL / ACCESSWIRE / June 15, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced that its RaDaR® assay, a personalized